10MO EMPOWER-Lung 1: Cemiplimab (CEMI) Monotherapy As First-Line (1L) Treatment of Patients (pts) with Brain Metastases from Advanced Non-Small Cell Lung Cancer (ansclc) with Programmed Cell Death-Ligand 1 (PD-L1) ≥50% — 3-Year Update

In phase III EMPOWER-Lung 1 study, 1L CEMI monotherapy resulted in significantly longer OS and PFS versus chemotherapy (CHEMO) for pts with aNSCLC with no actionable genomic aberrations, whose tumours express PD-L1 ≥50%. The study included pts with treated, clinically stable, baseline brain metastases, a hard-to-treat and underrepresented population in clinical trials. We previously reported improved OS and PFS with 1L CEMI versus CHEMO for this subgroup. In this post hoc analysis, we report 3-year outcomes.